Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

BACKGROUND: Most psoriasis patients have mild to moderate disease, commonly treated topically. Current topical agents have limited efficacy and undesirable side effects associated with long-term use. Tofacitinib is a small molecule Janus kinase inhibitor investigated for the topical treatment of pso...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A., Bissonnette, Robert, Gooderham, Melinda, Feldman, Steven R., Iversen, Lars, Soung, Jennifer, Draelos, Zoe, Mamolo, Carla, Purohit, Vivek, Wang, Cunshan, Ports, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048458/
https://www.ncbi.nlm.nih.gov/pubmed/27716172
http://dx.doi.org/10.1186/s12895-016-0051-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048458/
https://www.ncbi.nlm.nih.gov/pubmed/27716172
http://dx.doi.org/10.1186/s12895-016-0051-4

Ejemplares similares